GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rallybio Corp (NAS:RLYB) » Definitions » Asset Turnover

RLYB (Rallybio) Asset Turnover : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rallybio Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Rallybio's Revenue for the three months ended in Dec. 2024 was $0.04 Mil. Rallybio's Total Assets for the quarter that ended in Dec. 2024 was $73.56 Mil. Therefore, Rallybio's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Rallybio's annualized ROE % for the quarter that ended in Dec. 2024 was -66.69%. It is also linked to ROA % through Du Pont Formula. Rallybio's annualized ROA % for the quarter that ended in Dec. 2024 was -60.06%.


Rallybio Asset Turnover Historical Data

The historical data trend for Rallybio's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rallybio Asset Turnover Chart

Rallybio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial - - - - 0.01

Rallybio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rallybio's Asset Turnover

For the Biotechnology subindustry, Rallybio's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rallybio's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rallybio's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Rallybio's Asset Turnover falls into.


;
;

Rallybio Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Rallybio's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0.636/( (115.62+68.108)/ 2 )
=0.636/91.864
=0.01

Rallybio's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0.038/( (79.007+68.108)/ 2 )
=0.038/73.5575
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Rallybio  (NAS:RLYB) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Rallybio's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-44.176/66.236
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-44.176 / 0.152)*(0.152 / 73.5575)*(73.5575/ 66.236)
=Net Margin %*Asset Turnover*Equity Multiplier
=-29063.16 %*0.0021*1.1105
=ROA %*Equity Multiplier
=-60.06 %*1.1105
=-66.69 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Rallybio's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-44.176/73.5575
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-44.176 / 0.152)*(0.152 / 73.5575)
=Net Margin %*Asset Turnover
=-29063.16 %*0.0021
=-60.06 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Rallybio Asset Turnover Related Terms

Thank you for viewing the detailed overview of Rallybio's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Rallybio Business Description

Traded in Other Exchanges
N/A
Address
234 Church Street, Suite 1020, New Haven, CT, USA, 06510
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Executives
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jonathan I Lieber officer: See Remarks C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Wendy Chung director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Hui Liu director C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Christine A Nash director C/O RALLYBIO CORPORATION, 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510